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Abstract
Background: The purpose of this study was to evaluate the association of multi-genotype polymorphisms with
the stepwise progression of esophageal squamous cell cancer (ESCC) and the possibility of predicting those at
higher risk.
Methods: A total of 1,004 subjects were recruited from Feicheng County, China, between Jan. 2004 and Dec. 2007
and examined by endoscopy for esophageal lesions. These subjects included 270 patients with basal cell
hyperplasia (BCH), 262 patients with esophageal squamous cell dysplasia (ESCD), 226 patients with ESCC, and 246
controls with Lugol-voiding area but diagnosed as having normal esophageal squamous epithelial cells by
histopathology. The genotypes for CYP2E1 G1259C, hOGG1 C326G, MTHFR C677T, MPO G463A, and ALDH2 allele
genes were identified in blood samples collected from all participants.
Results: The alleles ALDH2 and MTHFR C677T were critical for determining individual susceptibility to esophageal
cancer. Compared to the ALDH 1*1 genotype, the ALDH 2*2 genotype was significantly associated with increased
risks of BCH, ESCD, and ESCC. However, the TT genotype of MTHFR C677T only increased the risk of ESCC. Further
analysis revealed that the combination of the high-risk genotypes 2*2/1*2 of ALDH 2 and TT/TC of MTHFR C677T
increased the risk of BCH by 4.0 fold, of ESCD by 3.7 fold, and ESSC by 8.72 fold. The generalized odds ratio (ORG)
of the two combined genotypes was 1.83 (95%CI: 1.55-2.16), indicating a strong genetic association with the risk of
carcinogenic progression in the esophagus.
Conclusions: The study demonstrated that the genotypes ALDH2*2 and MTHFR 677TT conferred elevated risk for
developing esophageal carcinoma and that the two susceptibility genotypes combined to synergistically increase
the risk.
Background
Esophageal cancer is the fourth most common cause of
cancer-related death in China. Esophageal cell carcinoma
(ESCC) is by far the most common subtype of esophageal
cancer, followed distantly by adenocarcinoma, which
accounts for less then 3% of all esophageal cancers in
high incidence areas of China [1].
The pathogenesis of ESCC is thought to include a step-
wise progression from basal cell hyperplasia (BCH) to
low-grade dysplasia (LGD), high-grade dysplasia (HGD),
carcinoma in situ, and finally invasive carcinoma. Japa-
nese and Chinese pathologists prefer to classify LGD as
mild-dysplasia or moderate-dysplasia, and HGD as
severe-dysplasia. They defined esophageal dysplasia as a
precancerous lesion of ESCC [2-5]. Epidemiological stu-
dies indicated that esophageal dysplasia was associated
with a significantly increased risk of developing invasive
ESCC [6-10].
Endoscopic screening with the Lugol dye method
combined with pathologic evaluation has proven useful
in screening for early esophageal cancer and in ascer-
taining the different stages of esophageal carcinogenesis
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expensive, however, and patients may experience pain
and discomfort, so only a small percentage of the popu-
lation may be willing to participate in this testing pro-
gram. With the development of molecular techniques,
however, it is now possible to employ useful biomarkers
to identify subjects at high-risk who should receive this
pathological screening test.
Recent studies have suggested that a variety of genes
may be associated with susceptibility to ESCC. These
include the aldehyde dehydrogenase-2 gene (ALDH2)
[12-14], the methylene tetrahydrofolate reductase gene
(MTFHR) [15-17], cytochrome P450 2E1 (CYP2E1)
[18,19], myeloperoxidase gene (MPO) [20,21], and the
human 8-oxoguanine glycosylase 1 gene (hOGG1) [22].
Indeed, there was a weak association between each of
these five susceptibility genes alone and esophageal cancer.
It is unclear, however, whether a combination of these sus-
ceptibility genes could be employed as useful biomarkers
to predict significantly elevated risk for ESCC.
In the present study, we developed a program for eva-
luation of esophageal lesions using endoscopic screening
with the Lugol dye method. The screening ran from Jan.
2005 to Dec. 2007 in Feicheng County, China. In addition
to endoscopic evaluation for various types of esophageal
lesions, the multi-genotype polymorphisms of CYP2E1
G1259C, hOGG1 C326G, MTHFR C677T, MPO G463A,
and ALDH2 genes were identified for each individual sub-
ject. Therefore, this program provided a valuable opportu-
nity to first examine the potential association between a
specific combination of genotypes and the carcinogenic
progression during ESCC, and then to evaluate the possi-
bility of using the genotype combination as a biomarker to
predict ESCC risk.
Methods
Study subjects
The human subject protocol for this study was approved
by the Ethics Committee of the Medical Faculty of the
Shandong Academy of Medical Sciences. Written
informed consent was obtained from all participants.
For subject recruitment, a questionnaire interview was
first conducted to collect information, such as sociodemo-
graphic characteristics, alcohol intake, tobacco use, and
family history of esophageal carcinoma. Then, a routine
physical examination, electrocardiogram, and abdomen
ultrasound were provided to all candidates. Those who
had liver diseases, cardiovascular diseases, lung diseases, or
head-and-neck diseases were excluded for further consid-
eration. All candidate subjects were given an endoscopic
staining examination with 1.2% iodine solution for evalua-
tion of esophageal lesions. Furthermore, for persons with a
non-staining area of the mucosa, random 4-quadrant
biopsy specimens were obtained at 2-cm intervals.
Specimens were processed by the standard procedure [5]
and histopathological diagnoses were made by two inde-
pendent pathologists.
A total of 10125 persons took part in the endoscopic
staining examination. Of these patients, 1364 had a non-
staining area of the mucosa and were diagnosed by histo-
pathologic analysis of biopsy tissue. These patients
included 280 with basal cell hyperplasia (BCH), 577 with
esophageal squamous cell dysplasia (ESCD), 94 with eso-
phageal squamous cell cancer (ESCC) at early stage, and
267 controls with normal esophageal squamous epithelial
cells. We randomly selected 50% of the ESCD for further
study using the program SPSS. Another 146 patients with
ESCC were referred from the Hospital of Feicheng
County. In total, 1004 subjects with pathological data were
available for the analysis, including 270 patients with BCH,
262 patients with ESCD, 226 patients with ESCC, and 246
controls with Lugol-voiding area but diagnosed as normal
by histopathology of esophageal squamous epithelial cells.
For genotype assays, 5-8 ml of blood were collected from
each participant in a sterile cryogenic vial and stored at
-70 ºC until processed.
The sample size was calculated by the Power 3.0 soft-
ware (http://dceg.cancer.gov/bb/tools/power). We recalcu-
lated the sample size based on the following parameters:
design: case-control study; case: control = 1:1; probability
of esophageal cancer = 0.001 for the aged 40-69; observed
minor allele frequency 0.1-0.25; a moderate genetic risk
effect (OR = 1.2-1.3); P-value = 0.05; 1-b = 0.8; additive
effect model OR = 3.0 of two genes exposure, the sample
size = 265. According to the actual sample sizes in the
study, the posterior powers (1-b), were 0.735, 0.796, 0.808
and 0.769 for the above four groups of ESCC, ESLD, BCH
and controls, respectively.
PCR-RFLP Polymorphism for MTHFR C677T, MPO G463A
and CYP2E1 G1259C
The PCR reaction was carried out in gradient PCR instru-
ment (Eppendorf, Germany). The reaction mixture con-
tained 25 ng DNA, 10 mM dNTP 0.5 μl, 10 × PCR Buffer
2.5 μl, 10uM of each primer (Table 1) and 0.5 units of Taq
DNA polymerase with the buffer (20 mmol/L Tris-HCl,
pH 8.4; 50 mmol/L KCl) in a volume of 25 μl.
PCR conditions were 95°C for minutes, followed by 35
cycles of 95°C for 60 seconds optimal annealing tempera-
ture × °C (Table 1) for 60 seconds and 72°C for 60 seconds
followed by a final extension step of 72°C for 7 minutes.
The 5 μlP C Rp r o d u c to fMTHFR C677T gene was
digested by a HinfI restriction enzyme. Digestion products
were visualized after electrophoresis on a 3% agarose gel
with ethidium bromide. Wild types (677CC) produced a
single band at 198bp. Heterozygotes (677CT) produced
198, 175, and 23bp fragments. Homozygous mutants
(677TT) produced 175 and 23bp fragments [16].
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an AciI restriction enzyme yielding three possible geno-
types which were defined by three distinct banding pat-
terns: A/A 289 and 61bp fragments, A/G 289, 169, 120,
and 6lbp fragments, and G/G 169, 120, and 6lbp fragments
[20].
The PCR product of CYP2E1 G1259C gene was
digested with PstI restriction endonuclease for 8 hours
at 37°C. Three possible genotypes were defined by three
distinct banding patterns: C1/C1 410bp fragment, C1/
C2 410, 290 and 120 bp fragments, and C2/C2 290- and
120-bp fragments [18].
PCR for ALDH2
The two pairs of primers shown in Table 1 were used in
the PRC assay. F1 and R1 were used to amplify the
ALDH2*1 allele (296bp), and F2 and R2 to amplify the
ALDH2*2 allele (203bp). Two 25 μL reaction tubes were
needed for each specimen to amplify ALDH2*1 (G) and
ALDH2*2 (A) respectively, each containing 100 ng
DNA, 0.12 mmol/L dNTPs, 12.5 pmol F1 (or R1) pri-
mer, 12.5 pmol F2 (or R2) primer, 0.5 U Taq polymer-
ase, and 2.5 μL 10 × PCR buffer (containing 15 mmol/L
MgCl2). The reaction tubes were heated to 95°C for 5
min followed by 30 cycles of 95°C for 60 s, 60°C for 60
s, 72°C for 60 s, and 72°C for 45 s, and then followed by
a final extension of 5 min at 72°C. 10 μLP C Rp r o d u c t s
were used in agarose gel electrophoresis and the electro-
phoresis result was photographed.
Two lanes were used for each specimen. If one showed
296 bp band and the other showed no band, the corre-
sponding genotype was ALDH2*1/2*1 (G/G); if one
showed 296 bp band and the other showed 203 bp band,
the corresponding genotype was ALDH2*1/2*2 (G/A); and
if one showed 203 bp band and the other showed no band,
the corresponding genotype was ALDH2*2/2*2 (A/A) [23].
PCR-SSCP analysis of hOGG1 C326G
The PCR product was denatured with formamide at 95°C
for 15 min, quenched on ice, and loaded to polyacrylamide
gels under several conditions. Visualization was performed
with a silver stain kit (Wako, Osaka, Japan) as described
[22]. The PCR product of hOGG1 C326G gene is digested
by Fnu4HI on the polyacrylamide gels showed C/C geno-
type is a band at 200bp, G/G genotype is a band at 100bp,
and C/G genotype is two bands at 200bp and 100bp.
Quality Control
The genotypes of the DNA samples were identified
without knowledge of the case or control status; 5%
were randomly selected as a sample set of cases and
controls that were genotyped by different investigators,
and the reproducibility was 100%. Each PCR procedure
was performed with a blank control (without DNA tem-
plate) and positive and negative controls. Cycle sequen-
cing PCR product was performed to confirm the
accuracy of this method of single-nucleotide polymorph-
isms (SNP) identification. When any of these controls
failed, the PCR was repeated for the batch of samples.
Statistical Analysis
Pearson’s Chi-Square and Kruskal-Wallis H tests were
used to examine differences in sociodemographic charac-
teristics, alcohol intake, tobacco use, and family history
of esophageal cancer among the four diagnostic groups
(Control, BCH, ESCD, and ESCC). Smoking index repre-
sents the number of cigarettes per day multiplied by the
years of smoking. Alcohol drinking index equals the
amount of alcohol consumed per month multiplied by
drinking years. Allele frequencies were calculated using
allele counting tests for Hardy-Weinberg equilibrium and
were analyzed by the Chi-square test. Odds ratios (ORs)
and 95% confidence interval (95%CI) were calculated in
the multinomial Logistic model after adjusting for the
variables of age, smoking index, and drinking index.
An additional analysis based on the generalized odds
ratio (ORG) was also performed. The ORG utilizes the
complete genotype distribution and provides an estimate
of the magnitude of the association between disease sta-
tus and genotype [24]. The ORG and 95%CI were
Table 1 PCR conditions for genotypes of test DNA genes in the study
Gene Primer sequence Annealing Restriction enzyme
MTHFR
C677T
F: 5’-TGA AGG AGA AGG TGT CTG CGG GA-3’
R: 5’-AGG ACG GTG CGG TGA GAG TG-3’
62°C HinfI
CYP2E1
G1259C
F: 5’-CCA GTC GAG TCT ACA TTG TCA-3’
R: 5’-TTC ATT CTG TCT TCT AAC TGG-3’
55°C PstI
hOGG1
C326G
F: 5’-GGA AGG TGC TTG GGG AAT-3’
R: 5’-ACT GTC ACT AGT CTC ACC AG-3’
58°C Fnu4HI
MPO
G463A
F: 5’-CGG TAT AGG CAC ACA ATG GTG AG-3’
R: 5’-GCA ATG GTT CAA GCG ATT C-3’
62°C AciI
ALDH2 F1: 5’-TCA TGC CAT GGC AAC TCC AGC-3’
R1: 5’-CCC ACA CTC ACA GTT TTC TCT TC-3’
F2: 5’-TAC GGG CTG CAG GCA TAC ACT A-3
R2: 5’-TGA TCC CCA GCA GGT CCT GAA-3’
60°C
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loaded from http://biomath.med.uth.gr). All other statis-
tical analysis were performed using SPSS (version 15.0),
and P< 0.05 (two-sided) was accepted as statistically
significant.
Results
Characteristics of demographic and selected variables
Demographic characteristics and selected variables are
shown in Table 2. All seven variables, including gender,
age, school years, income per year, smoking index, alco-
hol drinking status, and family history of esophageal
cancer were significantly different among the four
groups. Each variable also has a significant linear by lin-
ear association with the carcinogenic stages in transition
from normal esophageal mucosa to carcinoma.
Associations of CYP2E1 G1259C, MPO G463A, MTHFR
C677T, hOGG1 C326G, and ALDH2 genotypes with BCH,
ESCD, and ESCC
The frequency distribution of CYP2E1 G1259C, MPO
G463A, MTHFR C677T, hOGG1 C326G, and ALDH2
g e n o t y p e sa r es h o w ni nT a b l e3 .T h eH a r d y - W e i n b e r g
test for the control group showed that the distributions
of the five genotypes were in equilibrium.
As shown in Table 4 after adjusting for the potential
confounders gender, age, school years, income per year,
smoking index, alcohol drinking status, and family his-
tory of esophageal cancer, we found that polymorphism
of the ALDH2 genotype was associated with BCH,
E S C D ,a n dE S C C .C o m p a r e dt ot h eALDH 1*1 geno-
type, the ALHD 2*2 genotype was associated with signif-
icantly increased risks of BCH, ESCD, and ESCC (with
the adjusted OR = 4.15, 95% CI, 2.33-7.40 for BCH, OR
= 4.54, 95% CI 2.32-8.89 for ESCD, and OR = 3.38, 95%
CI 1.64-6.95 for ESCC). Furthermore, the TT genotype
of MTHFR C677T increased the relative risk in the
ESCC group, while the GG genotype of hOGG1 C326G
increased the risk in the ESCD group.
Based on the values of ORG,o n l yt h eMTHFR C677T
genotype (ORG = 1.16; 95%CI: 1.00-1.35) and ALDH 2
(ORG = 1.52; 95%CI: 1.30-1.77) genotype showed signifi-
cant genetic association with the risk of carcinogenic
progression of the esophagus.
Table 2 Distribution of selected variables in the BCH,
ESCD, ESCC and controls
Feature BCH
(n = 270)
ESCD
(n = 262)
ESCC
(n = 226)
Controls
(n = 246)
x
2(P
c)
Gender (n,%)
Male 185(68.5) 151 (57.7) 162 (71.7) 125(50.8) 29.062
Female 85(31.5) 111 (42.3) 64 (28.3) 121(49.2) (<0.001)
Age(yr) (n,%)
<50 70(26.0) 40(15.3) 38(16.8) 142(57.7) 150.471
50- 138(51.1) 138(52.7) 102(45.1) 66(26.8) (<0.001)
≥60 62(23.0) 84(32.1) 86(38.1) 38(15.4)
School (yr) (n,%)
≤6 110 (40.9) 148 (56.5) 144 (63.7) 102(41.5) 39.792
9 129(47.7) 92 (35.1) 72(31.9) 120(48.8) (<0.001)
≥10 31(11.5) 22 (8.4) 10(4.4) 24(9.8)
Income per year ($) (n,%)
<150 129(47.7) 134 (51.1) 98 (43.4) 164(66.7) 36.494
150- 117(43.4) 92(35.1) 94(41.6) 66(26.8) (<0.001)
≥350 24(8.9) 36(13.7) 34(15.0) 16(6.5)
Smoking index
a(n,%)
None 109 (40.4) 148 (56.9) 80 (35.4) 148(60.2) 60.087
<450 63 (23.4) 38(14.6) 36 (15.9) 48(19.5) (<0.001)
≥450 98 (36.2) 74(28.5) 110 (48.7) 50(20.3)
Alcohol drinking Status
b
(n,%)
None 114 (42.4) 136 (53.1) 76 (33.6) 138(56.1) 68.712
<100 43(16.0) 44(17.2) 32 (14.2) 62(25.2) (<0.001)
≥100 112(41.6) 76(29.7) 118 (52.2) 46(18.7)
Family history of esophagus cancer
(n,%)
None 231 (85.5) 2021(77.1) 190(84.1) 222(90.2) 17.027
yes 39 (14.5) 60(22.9) 36(15.9) 24(9.8) (<0.001)
a smoking index = cigarette/day × number of smoking years.
b alcohol
drinking ≥100g/day means heavy drinker.
c P : Chi-square test was for
proportions among the four groups.
Abbreviations: BCH, Basal cell hyperplasia; ESCD, esophageal squamous cell
dysplasia; ESCC, Esophageal Squamous cell cancer.
Table 3 Distribution of CYP2E1, MPO, MTHFR and ALDH2
genotypes in the BCH, ESCD, ESCC and controls, n(%)
Feature BCH ESCD ESCC Controls x
2&P
a
CYP2E1 G1259C
C2/C2 4(1.5) 0 0 11(4.5) 1.519
C1/C2 83(30.8) 73(27.9) 67(29.6) 62(25.0) 0.678b
C1/C1 183(67.7) 189(72.1) 159(70.4) 173(70.5)
MPO G463A
G/G 221(81.8) 234(89.2) 175(77.4) 191(77.8) 15.942
A/G 49(18.2) 28(10.8) 44(19.4) 52(21.2) 0.001
b
A/A 0 0 7(3.2) 2(1.0)
hOGG1 C326G
G/G 43(15.9) 26(10.1) 13(5.9) 26(10.4) 24.003
C/G 123(45.7) 160(60.9) 126(55.9) 123(50.0) <0.001
C/C 104(38.4) 76(29) 86(38.2) 97(39.6)
MTHFR C677T
T/T 45(16.7) 85(32.4) 64(28.4) 58 (23.6) 20.705
C/T 113(41.9) 82(31.3) 85(37.5) 97 (39.4) 0.002
C/C 112(41.4) 95(36.3) 77(34.1) 91 (37.0)
ALDH2
G/G(2*2) 106(39.4) 145(55.3) 76(33.6) 41(16.7) 80.423
A/G(1*2) 134(49.5) 85(32.5) 129(57.1) 164(66.6) <0.001
A/A(1*1) 30(11.1) 32(12.2) 21(9.3) 41(16.7)
aP : Chi-square test was for proportions among the four groups.
b : Kruskal-
Wallis H test. Abbreviations: BCH, Basal cell hyperplasia; ESCD, esophageal
squamous cell dysplasia; ESCC, Esophageal Squamous cell cancer.
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Subjects with either homozygous or heterozygous var-
iant alleles (2*2 or 1*2) of ALDH 2 had increased risk of
developing BCH, ESCD, and ESCC compared to those
who had wild type ALDH 2 (Table 4). Furthermore, TT
and CT genotypes of MTHFR C677T were found to
enhanced susceptibility to ESCC compared to the CC
genotype.
The frequencies of the various combinations of the
susceptible genotypes of ALDH 2a n dMTHFR C677T
genes were calculated and analyzed for their associated
risks of diseases (Tables 5 and 6). The OR values for the
associations of the combined susceptibility genotypes
with esophageal lesions was significantly higher than for
the individual genotypes (Table 6). For example, after
adjusting for the aforementioned seven potential con-
founders, the combinations of ALDH 2 2*2/1*2 and
MTHFR TT/TC genotypes were associated with signifi-
cantly increased risks for BCH, ESCD, and ESCC com-
pared to patients with the 1*1 ALDH 2 and CC MTHFR
C677T genotype. The ORs (95%CI) were 4.03(2.14-7.57)
for BCH, 3.70(1.74-7.87) for ESCD, and 8.72(3.24-23.48)
for ESCC. Furthermore, the ORG of the two combined
genotypes was 1.83(95%CI: 1.55-2.16), indicating a sig-
nificant genetic association with the risk of carcinogenic
progression in the esophagus.
Discussion
Feicheng County has a high incidence of esophageal
cancer compared to the rest of China. Worldwide mor-
tality rates have decreased from 75.82 per 100,000 in
1970-1974 to 57.22 per 100,000 in 2000-2004 [25]. In
the present study, we demonstrate that specific allelic
combination significantly increased the risk for esopha-
geal cancer (by as much as 8-fold). While reproducibility
of studies linking genotype to disease risk is often pro-
blematic, there are several strengths of this study. First,
the subjects in the study were diagnosed by biopsy, so
misclassification bias was very low. Our DNA collection
method avoided biases that may arise from single-center
or multi-center collection. Furthermore, several steps
were taken to ensure high quality and repeatability of
Table 4 Risk genotypes related to BCH, ESCD and ESCC in the multinomial logistic regression models
a
Factors BCH
OR(95%CI)
ESCD
OR(95%CI)
ESCC
OR(95%CI)
ORG(95%CI) #
MTHFR C677T
TT 0.91(0.59-1.40) 0.78(0.48-1.28) 1.85(1.02-3.34) 1.16(1.00-1.35)
CT 0.89(0.58-1.37) 0.56(0.34-1.03) 1.72(0.95-3.10)
TT&TC 0.90(0.62-1.32) 0.66(0.43-1.12) 1.71(1.01-2.91)
CC 1.00 1.00 1.00
MPO G463A
GG 1.09(0.64-1.86) 2.13(0.90-5.08) 0.96(0.52-1.78) 0.93(0.72-1.19)
GA&AA 1.00 1.00 1.00
CYP2E1 G1259C
C2/C2 & C1/C2 1.15(0.64-2.09) 0.79(0.38-1.62) 1,01(0.43-2.33) 0.94(0.77-1.14)
C1/C1 1.00 1.00 1.00
hOGG1 C326G
GG 1.56(0.71-3.43) 1.23(0.46-3.26) 0.50(0.14-1.81) 1.00(0.85-1.78)
GC 1.10(0.66-1.86) 2.33(1.24-4.36) 1.45(0.72-2.92)
GG&GC 1.2990.73-1.97) 2.08(1.14-3.76) 1.23(0.63-2.40)
CC 1.00 1.00 1.00
ALDH2
2*2 4.15(2.33-7.40) 4.54(2.32-8.89) 3.38(1.64-6.95) 1.52(1.30-1.77)
1*2 1.19(0.72-1.95) 0.65(0.34-1.22) 1.39(0.73-2.64)
2*2&1*2 1.73(1.07-2.81) 1.43(0.79-2.58) 1.80(0.97-3.38)
1*1 1.00 1.00 1.00
a: Adjusted for age, sex, income, school year, smoking, drinking and family history of esophageal cancer. Abbreviations: BCH, Basal cell hyperplasia; ESCD,
esophageal squamous cell dysplasia; ESCC, Esophageal Squamous cell cancer; ORG: generalized odds ratio.
#: ORG: calculated by the software “ORGGASMA” of the web site htpp://biomath.med.uth.gr.(note:: added 0.5 to zero frequency of cell).
Table 5 Distribution of subjects with the number of
susceptibility of the combination of the ALDH2 and
MTHFR genes in the four groups
ALDH2 MTHFR ESCC n,% ESCD n,% BCH n,% Normal n,%
2*2/1*2 TC/TT 163(72.1) 138(52.7) 150(55.5) 100(40.7)
2*2/1*2 CC 38(16.8) 84(32.1) 80(29.6) 54(22.0)
1*1 TC/TT 17(7.5) 26(9.9) 25(9.3) 52(21.1)
1*1 CC 7(3.1) 14(5.3) 15(5.6) 40(16.2)
Total 226 (100.0) 262(100.0) 270(100.0) 246(100.0)
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regions to prove the reliability, blinding of the operator
to the case-control status of samples to reduce observer
bias, and simultaneous analysis of case and control sam-
ples to avoid differential misclassification. Moreover, the
allele frequencies reported among normal controls in
this study were similar to those reported in previous
studies of Chinese subjects. In sum, these controls indi-
cated that our findings have high validity and reliability.
In the present study, we found that the ALDH2 geno-
type was associated with BCH, ESCD, and ESCC, the
main stages of carcinogenic transition in the esophagus.
Acetaldehyde is formed by the oxidation of ethanol by
alcohol dehydrogenase (ADH), and is eliminated by
aldehyde dehydrogenase (ALDH). The ALDH2 gene car-
ries two alleles, ALDH2*1 and ALDH2*2, with different
kinetic properties and distinct distributions among eth-
nicities [23,26]. The ALDH2*2 allele is found at a fre-
quency of only 50% in Orientals, while the ALDH2*1
allele is more predominant in Caucasians [26]. The
ALDH2*2 allele codes for an inactive ALDH2, and is clo-
sely associated with alcohol related cancers in the upper
aerodigestive tract [27-29]. The accumulation of acetal-
dehyde plays a protective role against excessive alcohol
consumption as it causes unpleasant reactions, including
“Oriental facial flushing” and other symptoms due to
alcohol sensitivity, such as headache, nausea, vomiting,
tachycardia, hypotension, and sleepiness [30]. Essentially,
a person harboring the ALDH2*2 allele may not become
a heavy drinker. Indeed, genetic epidemiologic studies
have indicated that the ALDH2*2 allele inhibits the
development of alcoholism. However, many studies
demonstrated that patients harboring ALDH2*2 allele
who are heavy drinkers were at increased risk of ESCC.
It is unknown why patients harboring the ALDH2*2
allele became heavy drinkers despite the unpleasant
reaction to acetaldehyde [28-31].
In the present study, heavy drinkers with ALDH2*2/
2*2, ALDH2*1/2*2, and ALDH2*1/2*1 genotypes com-
prised 3.9%, 25.5%, and 14.7% of the cancer group, and
2.5%, 20.0%, and 0.8% of the control group, respectively.
It is clear that persons harboring the ALDH2*2/2*2 gen-
otype are less likely to be heavy drinkers than those har-
boring the ALDH2*1/2*2 or ALDH2*1/2*1 genotypes.
Aside from the increased sensitivity of alcohol-induced
nausea, this may reflect a very low level of alcohol con-
sumption in Feicheng County, where living standards
are relatively low and the majority of farmers cannot
afford alcoholic beverages [32,33].
The TT genotype of the MTHFR gene had a signifi-
cantly positive association with ESCC (OR = 1.85, 95%
CI 1.02-3.34) but not with BCH or ESCD. There was
also a significant association between esophageal cancer
and the MTHFR TT genotype with which the patient
was also a heavy smoker. Associational studies linking
polymorphisms of the MTHFR C677T genotype with
ESCC risk have yielded inconsistent result. A meta-ana-
lysis of studies examined the association of the MTHFR
C667T polymorphism with risk of esophageal cancer
[34].
The association between esophageal cancer and
MTHFR enzyme activity is most likely related to the
metabolism of folic acid, as risk of esophageal cancer
depends on the status of folic acid intake. When folic
acid intake is sufficient, individuals with the MTHFR CT
or TT genotypes may actually have a decreased risk of
esophageal lesions because the lower MTHFR activity of
the 677TT allele may lead to an elevation in 5, 10-
methylenetetrahydrofolate, facilitating DNA synthesis. In
contrast, both impaired DNA methylation and DNA
synthesis/repair may become the primary mechanisms
of carcinogenesis in the presence of low folic acid intake
[16,35-37]. However, the TT genotype was not related
to BCH or ESCD, suggesting a weaker or absent linkage.
We present evidence that two susceptibility genes,
ALDH2*2 and MTHFR 677T, contribute to the process
of esophageal carcinogenesis. The combination of the
two high-risk genotypes 2*2/1*2 of ALDH 2 and TT/TC
of MTHFR C677T resulted in a 4-fold higher risk of
developing BCH, a 3.7-fold increased risk of ESCD, and a
Table 6 ORs (95%CI) of the susceptibility genotypes of the combination of the ALDH2 and MTHFR genes related to
lesions of esophagus
a
Crude OR(95%CI) Adjusted OR(95%CI)
ALDH2 MTHFR BCH ESCD ESCC BCH ESCD ESCC
2*2/1*2 TC/TT 4.00
(2.28-7.17)
3.92
(2.06-8.11)
9.31
(3.81-23.12)
4.03
(2.14-7.57)
3.70
(1.74-7.87)
8.72
(3.24-23.48)
2*2/1*2 CC 3.95 (2.16-7.42) 4.44
(2.25-9.60)
4.02
(1.58-10.94)
4.21
(2.14-8.29)
4.68
(2.11-10.38)
4.45
(1.54-12.87)
1*1 TC/TT 1.37
(0.65-2.50)
1.43
(0.67-3.29)
1.87
(0.68-5.45)
1.18
(0.56-2.49)
1.23
(0.51-2.95)
1.80
(0.57-5.68)
1*1 CC 1.00 1.00 1.00 1.00 1.00 1.00
a: Adjusted for age, sex, income, school year, smoking, drinking and family history of esophageal cancer. Abbreviations: BCH, basal cell hyperplasia; ESCD,
esophageal squamous cell dysplasia; ESCC, Esophageal Squamous cell cancer.
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C677T genes showed a significant association with ESCC
in our population.
In contrast to ALDH 2a n dMTHFR, polymorphisms
of CYP2E1 G1259C, MPO G463A, and hOGG1 C326G
genes were not associated with BCH, ESCD, or ESCC
risk in this study. These negative results may be attribu-
table to the fact that the study population came from
the same community where residents share a similar life
style and diet. This homogeneity may cause an over-
match, such that the association of these two metabolic
enzyme genes (CYP2E1, MPO) and one repair gene
(hOGG1) with lesions of the esophagus cannot be
demonstrated or is too low to estimate. In addition,
because these alleles were associated with smaller ORs
(<2.0) for risk of the diseases, this effects would not be
detected due to an allele null frequency less than 0.10.
The sample size, therefore, may not have been large
enough to detect an association.
Conclusion
The ALDH2*2 and MTHFR 677T alleles were associated
with higher susceptibility to esophageal cancer. Compared
with the ALDH 1*1 genotype, the ALHD 2*2 genotype was
associated with significantly increased risks for BCH,
ESCD, and ESCC, while the TT genotype of MTHFR
C677T increased the risk of ESCC. The generalized odds
ratio analysis confirmed these findings. Further analysis
revealed that the combination of these high-risk genotypes
(2*2/1*2 of ALDH 2 and TT/TC of MTHFR C677T) sig-
nificantly increased susceptibility for BCH, ESCD, and
ESSC (by 4.0, 3.7 and 8.72 fold, respectively). The ORG of
the two genotypes combined was 1.83(95%CI: 1.55-2.16),
indicating a significant genetic association between this
combined genotype and cancer of the esophagus.
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